Landmark trials in the medical oncology management of early stage breast cancer

Whitney Hensing, Cesar A. Santa-Maria, Lindsay L. Peterson, Jennifer Y. Sheng

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


With the advent of breast cancer screening programs, the majorities of patients with newly diagnosed breast cancer are diagnosed with early stage disease and are likely to experience cure with proper treatment. Significant advances have been made in the management of early-stage breast cancer to personalize treatment according to disease biology. This progress has led to improvement in survival outcomes and quality of life for our patients. In this review, we discuss landmark clinical trials in medical oncology that have shaped the current standard of care for early stage ER-positive, HER2-positive, and triple negative breast cancer.

Original languageEnglish
Pages (from-to)278-292
Number of pages15
JournalSeminars in Oncology
Issue number5
StatePublished - Oct 2020


  • Adjuvant
  • Breast cancer
  • Clinical trials
  • HER-2
  • Hormone receptor
  • Neoadjuvant trastuzumab
  • Pertuzumab
  • T-DM1
  • Trastuzumab emtansine
  • Triple negative


Dive into the research topics of 'Landmark trials in the medical oncology management of early stage breast cancer'. Together they form a unique fingerprint.

Cite this